Tumour hypoxia - A characteristic feature with a complex molecular background

Radiotherapy and Oncology

Volumn 81, Issue 2, 2006, Pages 119-121

  Eriksen, Jesper Grau ^a   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PIMONIDAZOLE;

ANGIOGENESIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CELL HYPOXIA; CELL POPULATION; CELL PROLIFERATION; CORRELATION ANALYSIS; DNA DAMAGE; DNA MICROARRAY; EDITORIAL; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW; TUMOR CELL; VASCULARIZATION;

CELL HYPOXIA; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750727425     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.09.005     Document Type: Editorial

References (27)

1. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49 (1989) 6449-6465
2. Horsman M.R., and Overgaard J. The oxygen effect and tumour microenviroment. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Arnold, London 58-168
3. Horsman M.R., and Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol 70 (2004) 301-309
4. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol 46 (1998) 135-146
5. Fenton B.M., Paoni S.F., and Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 72 (2004) 221-230
6. Horsman M.R., and Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Arnold, London 58-168
7. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluro-uracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Onvol 23 (2005) 79-87
8. Le Q.T., Taira A., Budenz S., et al. Mature results from a randomized phase II trial of cis-platin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106 (2006) 1940-1949
9. Horsman M.R. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 42 (1998) 701-704
10. Salmon H.W., and Siemann D.W. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol 73 (2004) 359-366
11. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
12. Koritzinsky M., Seigneuric R., Magagnin M.G., van den B.T., Lambin P., and Wouters B.G. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 76 (2005) 177-186
13. Sorensen B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
14. Hoskin P.J., Sibtain A., Daley F.M., Saunders M.I., and Wilson G.D. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 72 (2004) 159-168
15. Janssen H.L., Hoebers F.J., Sprong D., et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol 70 (2004) 91-97
16. Yaromina A., Zips D., Thames H.D., et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiother Oncol 81 (2006) 122-129
17. Yaromina A., Holscher T., Eicheler W., et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiother Oncol 76 (2005) 206-212
18. Quennet V., Yaromina A., Zips D., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81 (2006) 130-135
19. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
20. Jonathan R.A., Wijffels K.I., Peeters W., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
21. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (2002) 2595-2604
22. 2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol 77 (2005) 220-226
23. Petersen C., Eicheler W., Frommel A., et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 79 (2003) 469-477
24. Troost E.G., Bussink J., Kaanders J.H., et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76 (2005) 194-199
25. Buffa F.M., Bentzen S.M., Daley F.M., et al. Molecular profiles predict loco-regional control of head and neck squamous cell carcinoma in a randomised trial of conventional versus continous hyperfractionated accelerated radiotherapy (CHART). Clin Cancer Res (2004)
26. Eriksen J.G., Buffa F.M., Alsner J., Steiniche T., Bentzen S.M., and Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol 72 (2004) 275-282
27. Weinmann M., Belka C., Guner D., et al. Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. Oncogene 24 (2005) 5914-5922